TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07325292: A Randomized, Phase 3, Open-label Study to Investigate Pharmacokinetics, Safety, and Efficacy of Subcutaneous Compared to Intravenous Frexalimab in Adult Participants With Multiple Sclerosis

Sponsor: Sanofi · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 160 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$661,152

Rescue Site Savings

+$440,768

Unlock Full NCT07325292 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07325292 Rescue Dossier →